Research Article
Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Table 3
Correlation between the expression level of DLD and clinicopathological characteristics in BRCA.
| | Characteristic | Low expression of DLD | High expression of DLD | |
| | 541 | 542 | | | T stage, (%) | | | 0.060 | | T1 | 135 (12.5%) | 142 (13.1%) | | | T2 | 311 (28.8%) | 318 (29.4%) | | | T3 | 83 (7.7%) | 56 (5.2%) | | | T4 | 12 (1.1%) | 23 (2.1%) | | | N stage, (%) | | | 0.541 | | N0 | 262 (24.6%) | 252 (23.7%) | | | N1 | 168 (15.8%) | 190 (17.9%) | | | N2 | 60 (5.6%) | 56 (5.3%) | | | N3 | 41 (3.9%) | 35 (3.3%) | | | M stage, (%) | | | 0.019 | | M0 | 436 (47.3%) | 466 (50.5%) | | | M1 | 8 (0.9%) | 12 (1.3%) | | | Pathologic stage, (%) | | | 0.540 | | Stage I | 95 (9%) | 86 (8.1%) | | | Stage II | 301 (28.4%) | 318 (30%) | | | Stage III | 129 (12.2%) | 113 (10.7%) | | | Stage IV | 8 (0.8%) | 10 (0.9%) | | | Histological type, (%) | | | < 0.001 | | Infiltrating ductal carcinoma | 355 (36.3%) | 417 (42.7%) | | | Infiltrating lobular carcinoma | 130 (13.3%) | 75 (7.7%) | | | ER status, (%) | | | 0.204 | | Negative | 110 (10.6%) | 130 (12.6%) | | | Indeterminate | 1 (0.1%) | 1 (0.1%) | | | Positive | 410 (39.6%) | 383 (37%) | | | HER2 status, (%) | | | 0.405 | | Negative | 272 (37.4%) | 286 (39.3%) | | | Indeterminate | 8 (1.1%) | 4 (0.6%) | | | Positive | 81 (11.1%) | 76 (10.5%) | | | PAM50, (%) | | | 0.105 | | Normal | 27 (2.5%) | 13 (1.2%) | | | LumA | 301 (27.8%) | 261 (24.1%) | | | LumB | 91 (8.4%) | 113 (10.4%) | | | HER2 | 40 (3.7%) | 42 (3.9%) | | | Basal | 82 (7.6%) | 113 (10.4%) | | | Menopause status, (%) | | | 0.154 | | Pre | 103 (10.6%) | 126 (13%) | | | Peri | 19 (2%) | 21 (2.2%) | | | Post | 367 (37.8%) | 336 (34.6%) | | | Age, median (IQR) | 60 (50, 69) | 56 (48, 65) | 0.002 |
|
|
